A 9-amino acid peptide that breaks down Alzheimer's amyloid plaques reaches the brain within 5 minutes when delivered nasally — but is undetectable when given through the bloodstream.
Brain reached in 5 min via nose; undetectable via bloodJAL-TA9 has a blood half-life under 1 minute, making IV delivery impossible — but nasal administration delivers measurable levels to CSF in 10 minutes and the olfactory bulb in 5 minutes
What the researchers found
A small peptide (JAL-TA9) that can break down amyloid-beta — the toxic protein in Alzheimer's disease — successfully reaches the brain when delivered through the nose, but not when injected into the bloodstream. After nasal administration in rats, the peptide was detectable in cerebrospinal fluid at 0.115 μg/mL within 10 minutes, while IV injection produced undetectable brain levels.
The peptide has an extraordinarily short blood half-life (<1 minute), making IV delivery useless. But it's far more stable in cerebrospinal fluid than in blood, making the nose-to-brain route ideal. Brain distribution data showed the peptide first reaches the olfactory bulb (peak at 5 min), then moves sequentially to frontal brain (30 min) and occipital brain (60 min), confirming direct nose-to-brain transport.
Why it matters
One of the biggest challenges in Alzheimer's drug development is getting peptide therapeutics across the blood-brain barrier. This study elegantly solves that problem: by sniffing the peptide, it travels directly from the nasal cavity along the olfactory nerve into the brain — bypassing the blood entirely. Combined with the peptide's ability to actually degrade amyloid-beta plaques, this represents a two-in-one breakthrough: a therapeutic peptide and a viable delivery route.
The numbers in context
9-amino acid peptide (YKGSGFRMI) · CSF level: 0.115 μg/mL at 10 min (nasal) vs undetectable (IV) · blood half-life: <1 min · olfactory bulb peak: 5 min · frontal brain: 30 min · occipital brain: 60 min
How the study worked
Pharmacokinetic study in rats and mice. IV injection was performed to measure plasma clearance. Stability was tested in plasma, whole blood, and CSF in vitro. Nasal and systemic (IV in rats, intraperitoneal in mice) administration were compared by measuring peptide concentrations in CSF and brain regions over time using validated analytical methods.
Who was studied
Rats (Sprague-Dawley) and mice used for pharmacokinetic studies
What this study cannot tell us
Animal study only — nasal anatomy and olfactory pathway differ between rodents and humans. No efficacy testing (amyloid plaque clearance) was performed in vivo — only delivery was measured. The peptide's amyloid-cleaving activity was previously demonstrated but not confirmed in this delivery context. Human nasal delivery efficiency is typically lower than in rodents. Long-term safety and tolerability of repeated nasal dosing were not assessed.
How to read the evidence
Well-designed preclinical pharmacokinetics study with clear head-to-head comparison of delivery routes. Published in a reputable pharmaceutical journal. However, it's entirely animal-based, and no efficacy (amyloid clearance or cognitive improvement) was tested. Early-stage evidence.
When this study was published
Published in 2025. This is a very recent study at the cutting edge of intranasal peptide delivery for neurodegenerative diseases. The nose-to-brain delivery field is advancing rapidly with new formulation technologies.
The bigger picture
The blood-brain barrier is the single biggest obstacle to developing brain-targeted peptide drugs. Intranasal delivery is one of the most promising solutions, and this study provides a textbook demonstration of the route: a peptide that's completely useless when injected into blood reaches therapeutic levels in the brain when delivered through the nose. If this approach works in humans, it could enable a whole class of peptide therapeutics for Alzheimer's and other neurodegenerative diseases.
Questions still open
- Does the JAL-TA9 peptide actually reduce amyloid plaques and improve cognition when delivered nasally to Alzheimer's model mice?
- Can repeated nasal dosing maintain sufficient brain peptide levels for chronic Alzheimer's treatment?
- Will the nose-to-brain efficiency hold up in larger animals and humans, where the olfactory epithelium is proportionally smaller?
Common questions
How does a peptide get from the nose to the brain?
What makes JAL-TA9 different from other Alzheimer's peptide approaches?
Read the original research
Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-β.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 208, 114661
Citation
Hatakawa, Yusuke; Tanaka, Akiko; Furubayashi, Tomoyuki; Katsumi, Hidemasa; Nakamura, Rina; Konishi, Motomi; Akizawa, Toshifumi; Sakane, Toshiyasu. (2025). Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-β.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 208, 114661. https://doi.org/10.1016/j.ejpb.2025.114661